These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
411 related articles for article (PubMed ID: 30202085)
61. Local Tumor Treatment in Combination with Systemic Ipilimumab Immunotherapy Prolongs Overall Survival in Patients with Advanced Malignant Melanoma. Theurich S; Rothschild SI; Hoffmann M; Fabri M; Sommer A; Garcia-Marquez M; Thelen M; Schill C; Merki R; Schmid T; Koeberle D; Zippelius A; Baues C; Mauch C; Tigges C; Kreuter A; Borggrefe J; von Bergwelt-Baildon M; Schlaak M Cancer Immunol Res; 2016 Sep; 4(9):744-54. PubMed ID: 27466265 [TBL] [Abstract][Full Text] [Related]
62. Pembrolizumab Exposure-Response Assessments Challenged by Association of Cancer Cachexia and Catabolic Clearance. Turner DC; Kondic AG; Anderson KM; Robinson AG; Garon EB; Riess JW; Jain L; Mayawala K; Kang J; Ebbinghaus SW; Sinha V; de Alwis DP; Stone JA Clin Cancer Res; 2018 Dec; 24(23):5841-5849. PubMed ID: 29891725 [TBL] [Abstract][Full Text] [Related]
63. Combined low-dose ipilimumab and pembrolizumab after sequential ipilimumab and pembrolizumab failure in advanced melanoma. Kirchberger MC; Hauschild A; Schuler G; Heinzerling L Eur J Cancer; 2016 Sep; 65():182-4. PubMed ID: 27501507 [TBL] [Abstract][Full Text] [Related]
64. Efficacy and Safety of Pembrolizumab in Patients Enrolled in KEYNOTE-030 in the United States: An Expanded Access Program. Gangadhar TC; Hwu WJ; Postow MA; Hamid O; Daud A; Dronca R; Joseph R; O'Day SJ; Hodi FS; Pavlick AC; Kluger H; Oxborough RP; Yang A; Gazdoiu M; Kush DA; Ebbinghaus S; Salama AKS J Immunother; 2017; 40(9):334-340. PubMed ID: 29028788 [TBL] [Abstract][Full Text] [Related]
65. Evaluation of dosing strategy for pembrolizumab for oncology indications. Freshwater T; Kondic A; Ahamadi M; Li CH; de Greef R; de Alwis D; Stone JA J Immunother Cancer; 2017; 5():43. PubMed ID: 28515943 [TBL] [Abstract][Full Text] [Related]
66. Ipilimumab in real-world clinical practice: efficacy and safety data from a multicenter observational study. Russi A; Damuzzo V; Chiumente M; Pigozzo J; Cesca M; Chiarion-Sileni V; Palozzo AC J Chemother; 2017 Aug; 29(4):245-251. PubMed ID: 28398170 [TBL] [Abstract][Full Text] [Related]
67. The effect of timing of stereotactic radiosurgery treatment of melanoma brain metastases treated with ipilimumab. Cohen-Inbar O; Shih HH; Xu Z; Schlesinger D; Sheehan JP J Neurosurg; 2017 Nov; 127(5):1007-1014. PubMed ID: 28059663 [TBL] [Abstract][Full Text] [Related]
69. Clinical Activity of Ipilimumab in Acral Melanoma: A Retrospective Review. Johnson DB; Peng C; Abramson RG; Ye F; Zhao S; Wolchok JD; Sosman JA; Carvajal RD; Ariyan CE Oncologist; 2015 Jun; 20(6):648-52. PubMed ID: 25964307 [TBL] [Abstract][Full Text] [Related]
70. [Severe ipilimumab-induced ulcerative colitis remitting after infliximab therapy and secondary switching with pembrolizumab]. Yelehe-Okouma M; Granel-Brocard F; Hudziak H; Schmutz JL; Gillet P Therapie; 2018; 73(3):291-293. PubMed ID: 29203065 [No Abstract] [Full Text] [Related]
71. A Phase Ib Study of Pembrolizumab as Second-Line Therapy for Chinese Patients With Advanced or Metastatic Melanoma (KEYNOTE-151). Si L; Zhang X; Shu Y; Pan H; Wu D; Liu J; Lou F; Mao L; Wang X; Wen X; Gu Y; Zhu L; Lan S; Cai X; Diede SJ; Zhou Y; Ge J; Li J; Wu H; Guo J Transl Oncol; 2019 Jun; 12(6):828-835. PubMed ID: 30981094 [TBL] [Abstract][Full Text] [Related]
72. Focal radiation necrosis of the brain in patients with melanoma brain metastases treated with pembrolizumab. Du Four S; Janssen Y; Michotte A; Van Binst AM; Van den Begin R; Duerinck J; Neyns B Cancer Med; 2018 Oct; 7(10):4870-4879. PubMed ID: 30133176 [TBL] [Abstract][Full Text] [Related]
73. Baseline laboratory parameters predicting clinical outcome in melanoma patients treated with ipilimumab: a single-centre analysis. Gambichler T; Brown V; Steuke AK; Schmitz L; Stockfleth E; Susok L J Eur Acad Dermatol Venereol; 2018 Jun; 32(6):972-977. PubMed ID: 29024038 [TBL] [Abstract][Full Text] [Related]
74. Real-world use, safety, and survival of ipilimumab in metastatic cutaneous melanoma in The Netherlands. Jochems A; Leeneman B; Franken MG; Schouwenburg MG; Aarts MJB; van Akkooi ACJ; van den Berkmortel FWPJ; van den Eertwegh AJM; Groenewegen G; de Groot JWB; Haanen JBAG; Hospers GAP; Kapiteijn E; Koornstra RH; Kruit WHJ; Louwman MWJ; Piersma D; van Rijn RS; Ten Tije AJ; Vreugdenhil G; Wouters MWJM; Uyl-de Groot CA; van der Hoeven KJM Anticancer Drugs; 2018 Jul; 29(6):572-578. PubMed ID: 29659371 [TBL] [Abstract][Full Text] [Related]
75. Immunogenicity of pembrolizumab in patients with advanced tumors. van Vugt MJH; Stone JA; De Greef RHJMM; Snyder ES; Lipka L; Turner DC; Chain A; Lala M; Li M; Robey SH; Kondic AG; De Alwis D; Mayawala K; Jain L; Freshwater T J Immunother Cancer; 2019 Aug; 7(1):212. PubMed ID: 31395089 [TBL] [Abstract][Full Text] [Related]